30.6 C
Vientiane
Tuesday, July 8, 2025
spot_img
Home Blog Page 360

BOBA YOU X ME: TAIWAN’S FIRST-EVER CULTURAL AND ARTISTIC BUBBLE TEA EXHIBITION BY ORBITEL INTERNATIONAL, A GLOBAL LEADER OF INSTANT FOODS

A cultural reimagining of bubble tea through contemporary art…

Orbitel International’s O’s Bubble reinterprets Taiwan’s most iconic drink as a creative catalyst

LOS ANGELES, April 25, 2025 /PRNewswire/ — In a city synonymous with its bubble tea culture, Orbitel International, under its creative brand O’s Bubble, is flipping the script on how brands engage with culture.

In the quiet act of making, connection begins — BOBA YOU X ME, by Orbitel International Corp., believes in the stories we build when we believe in ourselves.
In the quiet act of making, connection begins — BOBA YOU X ME, by Orbitel International Corp., believes in the stories we build when we believe in ourselves.

Their latest endeavor — BOBA YOU X ME — launches this April as Taiwan’s first-ever cultural and artistic bubble tea exhibition. Through this historic collaboration between an FMCG leader and four Taiwanese artists, the project reshapes a humble drink into a symbol of resilience, connection, and transformation.

Opening April 26 at Node94 in Taipei, the exhibition runs until May 10 and coincides with “BubbleTeaDay” (April 30). Across 15 days, visitors will encounter mirrored floors, figurative sculptures, and kinetic installations that reframe the ubiquitous boba pearl as a trans-cultural icon.

When FMCG Meets Fine Art: A First in Taiwan 

Unlike traditional brand showcases, BOBA YOU X ME is an immersive artistic provocation, a quiet divergence from commercial tropes. Orbitel International doesn’t simply sponsor this project; it co-creates it. Behind the vision is a team of creatives who saw in boba not just nostalgia, but narrative, led by the mind of Orbitel International’s own Creative Director, Ken Hsieh.

We believe in the elasticity of Taiwan’s culture — how it bounces across oceans, soft but strong,” said Fanny Chen, Co-Founder and CEO of Orbitel International. “This isn’t about selling drinks. This is about sending Taiwan’s creative voice abroad, shaped by artists, sustained by community.”

Four Artists, Four Interpretations of ‘Connection’

Ken Hsieh – The Creative Brainchild Behind the Expo,

“Design is my language. But art is how I ask questions.”

As the project’s conceptual lead and Creative Director of Orbitel International, Hsieh embodies the intersection of design, emotion, and brand culture. A recipient of iF Design, Red Dot, and Lahti Triennale honors, his dual life as a painter and designer has made him one of Taiwan’s most versatile creative voices. His curatorial vision threads the show together — part visual poetry, part cultural invitation. 

Rong-Chih Huang – Curating Play and Participation,

“A good exhibition invites reflection. A great one invites response.”

As a senior curator and education lead at the Ju Ming Museum, Huang merges pedagogy with participation. His practice builds bridges between contemporary art, children’s imagination, and social spaces. 

Chi-Hsuan Hsieh – Sculpting Silence,

“Sculpture lets me anchor fleeting things — a smile, a season, a goodbye.”

Recipient of the 2024 Kaohsiung Art Award, Hsieh’s sculptural lexicon spans the monumental and the miniature. His works are about presence — sometimes still, often aching — always reflective of a world in transition. 

Shang-Fu Tsai – Assemblage of Absurdity, 

“I build misfits. Things that twitch, blink, creak—like us, like memory.”

Known for reimagining discarded materials into mechanical storytelling, Tsai explores human quirks through malfunctioning installations. His practice — part satire, part kinetic theatre — teases at the logic of the everyday. 

A Soft Power Statement 

In a world chasing speed and sales,  Orbitel International chooses a different pace — one led by artistic sincerity and cultural integrity. Through BOBA YOU X ME, the brand affirms that commerce and creativity are not in opposition, but co-conspirators in building lasting meaning.

“We’re not just serving beverages,” says Charlotte Chen Vice President  Sales & Marketing, Orbitel International, “We’re serving stories. Each smile, each sip, each sculpture — it all speaks to how we connect, how we belong, and how we imagine.”

Exhibition Details  for BOBA YOU X ME 

  • Dates: April 26May 10, 2025
  • Venue: Node94, B1, No. 94 Chaozhou St, Da’an District, Taipei
  • Opening Ceremony: April 26 at 11:00 AM
  • Public Hours: Weekends 11:00–19:00 | Friday 13:00-19:00 | Weekdays 13:00–18:00
  • Artist Dialogue Salon: May 3 at 14:00 PM, at Naturdise Café

For all images please click on BOBA YOUXME-download

For more information about Orbitel Internation, visit https://orbitelinternational.com

https://osbubble.com 

Media Inquiries & RSVP 

We warmly welcome friends from the media in Taiwan and all across the globe (if you are in Taiwan), to join us in experiencing this cultural milestone. For interviews, images, press previews, or curated walk-throughs, please contact: 

Name: Nina Jen

Title: Marketing Manager

Email: marketing@orbitel.com.tw

Democracy News Alliance – Australia’s next government must mend structural cracks appearing in its political, economic and social foundation, report finds

LOS ANGELES, US – Newsaktuell – 25 April 2025 – Australia boasts some of the world’s most sophisticated political institutions and one of its wealthiest economies. But this veneer of success masks deeper structural issues — and a “ticking time bomb” of overreliance on extractive industries must be addressed under Australia’s next government, a new report recommends.

Recent polls suggest that the upheaval caused by U.S. President Donald Trump is damaging centre-right political parties in Australia, which could spell defeat for conservative Opposition Leader Peter Dutton (right) and garner a win in the upcoming election for Prime Minister Anthony Albanese (left) of the Labor Party, who had earlier been projected to lose. (Photo by Tracey Nearmy/AFP) / The use of this image for editorial purposes is permitted and free of charge provided that all conditions of use are complied with. Publication must use image credits.
Recent polls suggest that the upheaval caused by U.S. President Donald Trump is damaging centre-right political parties in Australia, which could spell defeat for conservative Opposition Leader Peter Dutton (right) and garner a win in the upcoming election for Prime Minister Anthony Albanese (left) of the Labor Party, who had earlier been projected to lose. (Photo by Tracey Nearmy/AFP) / The use of this image for editorial purposes is permitted and free of charge provided that all conditions of use are complied with. Publication must use image credits.

Cracks have begun to show in the country’s façade of optimism, prosperity and progress, according to an Australia BGI Report on the country’s governance performance, released eight days before the May 3 election.

According to the report, the country’s economy continues to rely heavily on environmentally harmful extractive industries, while economic centralization in only a handful of cities has driven up housing costs. Racial tensions, including the displacement of Indigenous populations, remain unresolved.

This is resulting in “rising political polarization, deepening inequality and heightening exposure to the deeper geopolitical tensions emerging between the U.S. and China,” said the report.

Based on the Berggruen Governance Index (BGI), the report was conducted by researchers from the Los Angeles-based Berggruen Institute think tank, the Luskin School of Public Affairs at the University of California Los Angeles (UCLA) and the Hertie School, a German university.

According to the report, Australia has long benefited from favourable economic, geopolitical and demographic conditions. Its cities are ranked as some of the most livable in the world and it scores highly on almost all governance measures in the BGI, which analyzes the relationship between democratic accountability, state capacity and the provision of public goods.

But the country isn’t exempt from the same challenges to democracy, prosperity, and social cohesion that similar countries are facing, according to the report.

Eroding public trust in government is providing “the backdrop for a hotly contested federal election,” during which the centre-left Labor Party under Prime Minister Anthony Albanese is seeking to defend its majority against Opposition Leader Peter Dutton and the centre-right Liberals.

While the Labor Party was previously projected to lose after a lacklustre post-pandemic economic recovery, it has recently risen in the polls — a reversal mirroring a similar trend in Canada, in which U.S. President Donald Trump has amplified negative associations with conservatism. Now, the Australian Labor Party is projected to win by a slim margin.

Another factor influencing the election is rental affordability, which reached its worst level on record in 2025, according to the REA Group, a company in the real estate industry. This trend is pushing younger voters toward the Australian Green Party, which has made reform on the housing market a central part of its policy agenda, the Australia BGI Report said.

However, in the 2022 election, 12 per cent of the national vote translated into just 2.5 per cent of seats for the Greens — a pattern that “could repeat itself in 2025 due to the country’s preferential voting system.”

Australia’s electoral system uses a preferential voting system rather than the ‘first-past-the-post’ method common in many other Anglophone democracies, which conceals a “darker history of Indigenous dispossession and racial discrimination.” It’s also one of only 22 countries in the world that require citizens to vote.

However, the stresses that have plagued Albanese’s government “will persist regardless of who prevails in May,” said the BGI report.

Australia generally resembles wealthy Western European and North American countries on the 2024 Berggruen Governance Index, scoring highly on democratic accountability. It’s ranked as one of only 25 “full democracies” by the Economist Intelligence Unit.

But, despite ranking 9th globally in GDP per capita, Australia ranks only 99th worldwide in the Economic Complexity Index (ECI).

“Although Australia is blessed with bountiful natural resources, its political economy is also constrained by this very endowment,” said the Australia BGI Report. “Its reliance on extractive industries has reduced the incentive to diversify and weakened other parts of the economy.”

Iron ore, coal, petroleum, gold, and other minerals comprise the five largest products sold abroad, accounting for more than half of all exports.

Instead of moving away from this reliance, “Australia has in many ways doubled down,” said the report. Australia is the world’s largest coal exporter and accounts for more than half of the world’s lithium, with most of it going to China for battery manufacturing.

Therein lies another issue. While Australia is increasingly economically dependent on China, it has also long relied on the U.S. security guarantee. In the context of a growing U.S.-China rivalry, this puts Australia in a precarious position, said the report, being “economically tethered to one superpower, while militarily aligned with another.”

To move past these problems, Australia will have to “leverage its impressive state capacity and strong educational system to develop a more advanced services sector and more complex manufacturing,” said the Australia BGI Report.

The next government will need to focus on the “domestic essentials of growth” such as housing market reforms, as well as building economic complexity, to ensure internal and external stability, the report’s researchers conclude. Only with a more complex economy “can Australia ensure future growth and reduce vulnerability to foreign powers like China and the U.S.”

———————————————-

This text and the accompanying material (photos and graphics) are an offer from the Democracy News Alliance, a close co-operation between Agence France-Presse (AFP, France), Agenzia Nazionale Stampa Associata (ANSA, Italy), The Canadian Press (CP, Canada), Deutsche Presse-Agentur (dpa, Germany) and PA Media (PA, UK). All recipients can use this material without the need for a separate subscription agreement with one or more of the participating agencies. This includes the recipient’s right to publish the material in own products.

The DNA content is an independent journalistic service that operates separately from the other services of the participating agencies. It is produced by editorial units that are not involved in the production of the agencies’ main news services. Nevertheless, the editorial standards of the agencies and their assurance of completely independent, impartial and unbiased reporting also apply here.

Hashtag: #DemocracyNewsAlliance

The issuer is solely responsible for the content of this announcement.

Meihua International Medical Technologies Co., Ltd. Reports 2024 Financial Year Results

YANGZHOU, China, April 25, 2025 /PRNewswire/ — Meihua International Medical Technologies Co., Ltd. (“MHUA” or the “Company”) (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, today announced its financial results for the fiscal year ended December 31, 2024. All amounts below are in U.S. dollars.

Fiscal Year 2024 Financial Metrics:

  • Revenues remained stable and decreased slightly to $96.91 million for the year ended December 31, 2024, from approximately $97.10 million for the year ended December 31, 2023. The decrease was mainly due to the Company’s disposal of Hainan Guoxie Technology Group Co. Ltd (“Hainan Guoxie”).
  • Gross profit was approximately $33.30 million for the year ended December 31, 2024, compared with approximately $33.20 million for the year ended December 31, 2023.
  • Gross profit margin was 34% for both the years ended December 31, 2023 and 2024.
  • Income from operations was approximately $14.31 million for the year ended December 31, 2024, compared to approximately $14.67 million for the year ended December 31, 2023.
  • Net income was approximately $10.84 million for the year ended December 31, 2024, compared to approximately $11.59 million for the year ended December 31, 2023.

 

For the Years Ended December 31

(in $ millions, except earnings per share;
differences due to rounding)

2024

2023

%Change

Revenues

$

96.9

$

97.1

(0.2)

%

Gross profit

33.3

33.2

0.3

%

Gross margin

34

%

34

%

Flat

Income from operations

14.3

14.7

(2.5)

%

Net income attributable to shareholders

10.8

11.6

(6.5)

%

Net income per share – Basic and Diluted

0.40

0.49

(18.4)

%

Mr. Yongjun Liu, Chairman of the Company, commented, “In 2024, against a backdrop of a moderate macroeconomic recovery, we maintained our focus on advancing our strategic transition toward high-end medical products and enhancing operational efficiency. Our full-year revenue remained stable at $96.91 million, with gross profit increasing slightly by 0.3% year-over-year to $33.3 million and a solid gross margin of 34.0%. We ended the year with a healthy cash position of $17.3 million and improved operating cash flow, providing a strong foundation for our ongoing strategic initiatives. We believe that these results underscore the strength and resilience of our business model and our ability to optimize operations while sharpening our product focus.

“As part of our transformation, we completed the sale of our controlling equity stake in Hainan Guoxie in early 2024 and closed on a $6.0 million tranche under our previously announced securities purchase agreement in December 2024. This enabled us to reallocate capital toward higher-growth opportunities. We also made significant progress on the construction of our integrated medical industrial park in Boao Hope City, Hainan Province – the cornerstone of our long-term strategy. We believe that this facility, supported by national-level preferential policies from Qionghai City, will bring R&D, manufacturing, logistics and commercialization together under one roof, with plans in place to roll out advanced technologies, including minimally invasive surgical robots and smart home-use medical devices. The medical park is expected to be completed by mid-2025 and we anticipate that it will play a central role in accelerating our transition toward premium consumables and intelligent healthcare products.

Innovation continues to be the focus of our business. In May 2024, we launched our AI-powered Speed Fox warehouse management and logistics platform, significantly enhancing supply chain efficiency and customer satisfaction. In July, we participated in the world’s second-ever remote robotic lobectomy, marking a breakthrough in surgical innovation. These milestones reflect our growing capability to deliver advanced, technology-driven solutions to partners and customers globally. Looking ahead, we remain committed to strengthening our global and domestic distribution networks, expanding our high-end medical product portfolio, and further integrating AI to drive operational excellence and long-term value for our stakeholders.”

Fiscal Year 2024 Financial Results:

Revenues

Revenues decreased by approximately $0.19 million to $96.91 million for the year ended December 31, 2024 from approximately $97.10 million for the year ended December 31, 2023. The decrease was mainly due to the disposal of our subsidiary, Hainan Guoxie.

Cost of revenues

Cost of revenues primarily include cost of materials, direct labor costs, overhead, and other related incidental expenses that are directly attributable to the Company’s principal operations. Cost of revenues decreased by approximately $0.29 million, or approximately 0.5%, to $63.61 million for the year ended December 31, 2024 from approximately $63.90 million for the year ended December 31, 2023. The decrease was generally in line with an overall decrease in the cost of revenue, except for certain fixed costs such as lease expense and salary of administrative employees in the Company’s production department.

Gross profit and margin

Gross profit increased by approximately $0.10 million, or approximately 0.3%, to $33.30 million for the year ended December 31, 2024 from approximately $33.20 million for the year ended December 31, 2023. Gross profit margin remained consistent at 34% for the years ended December 31, 2023 and 2024.

Operating costs and expenses

Our operating costs and expenses consisted of selling expenses, general and administrative expenses and research and development expenses.

– Selling

Selling expenses decreased by approximately $0.66 million, or approximately 9%, to $6.64 million for the year ended December 31, 2024 from approximately $7.30 million for the year ended December 31, 2023. The decrease was mainly attributable to the combined effects of the following:

(a) Our consulting fees decreased to nil for the year ended December 31, 2024 from approximately $0.78 million for the year ended December 31, 2023. The Company signed a contract with a third-party consultant on October 12, 2023 in order to conduct market research and analysis on the Company’s main basic medical consumables and robotic surgical systems in the U.S. and related overseas countries. There was no such expense for the year ended December 31, 2024.

(b) Our transportation expenses increased by approximately $0.15 million, or approximately 6%, to $2.47 million for the year ended December 31, 2024 from $2.32 million for the year ended December 31, 2023. The increase in business travel was due to an increase in demand for customer orders.

– General and administrative expenses

General and administrative expenses increased by approximately $1.24 million, or approximately 19%, to $7.78 million for the year ended December 31, 2024, from approximately $6.54 million for the year ended December 31, 2023. The increase was primarily due to (a) legal costs increasing by approximately $1.35 million from $nil for the year ended December 31, 2023 to approximately $1.35 million for the year ended December 31, 2024; (b) entertainment expenses increasing by $0.07 million from $1.22 million for the year ended December 31, 2023 to approximately $1.29 million for the year ended December 31, 2024; (c) conference fee increasing by $0.06 million from $1.22  million for the year ended December 31, 2023 to $1.29 million for the year ended December 31, 2024; offset by (d) insurance expenses decreasing by $0.11 million from $0.12 million for the year ended December 31, 2023 to $5,067 for the year ended December 31, 2024, and (e) other expenses decreasing by approximately $0.11 million from $0.34 million for the year ended December 31, 2023 to approximately $0.23 million for the year ended December 31, 2024.

– Research and development expenses

Research and development expenses increased by approximately $0.70 million, or approximately 26%, to $3.46 million for the year ended December 31, 2024, from approximately $2.75 million for the year ended December 31, 2023. The increase was mainly due to an increase in sample manufacturing expenses.

Income from operations

As a result of the factors described above, our income from operations decreased by approximately $0.36 million, or approximately 2.5%, to $14.31 million for the year ended December 31, 2024 from approximately $14.67 million for the year ended December 31, 2023.

Income tax expense

The provision for income taxes decreased by approximately $0.67 million, or approximately 19%, to $2.79 million for the year ended December 31, 2024, from approximately $3.46 million for the year ended December 31, 2023. The decrease was mainly due to a decrease of taxable income in 2024.

Net income

Our net income decreased by approximately $0.75 million, or approximately 7%, to $10.84 million for the fiscal year ended December 31, 2024 from approximately $11.59 million for the fiscal year ended December 31, 2023.

Recent developments

On February 26, 2024, the Company transferred 45% of the equity interest in Hainan Guoxie from Kang Fu International Medical to Jiangsu Huadong, and the remaining 10% equity interest was sold to a third party, Yangzhou Boxin Medical Equipment Co., Ltd. in exchange for $637,940 (RMB4.4 million) in consideration. After the transaction, the Company no longer controls Hainan Guoxie, thus the Company deconsolidated Hainan Guoxie upon the completion of the transaction.  

Effective December 26, 2024, the Company entered into an amendment (the “Amendment”) to the securities purchase agreement, originally dated December 27, 2023 (the “SPA”), between the Company and Anson Investments Master Fund LP and Anson East Master Fund LP for the sale of up to $50.50 million in convertible notes and warrants. Under the Amendment, the parties agreed that there would only be the single $6,000,000 closing under the SPA, which occurred on January 2, 2024, and would be no additional closings under the SPA.

About Meihua International Medical Technologies Co., Ltd.

Meihua International Medical Technologies Co., Ltd. is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as HDPE bottles for tablets and LDPE bottles for eye drops, throat strips, and anal bags, and Class II and III disposable medical devices, such as disposable identification bracelets, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, medical catheters, uterine tissue suction tables, virus sampling tubes, disposable infusion pumps, electronic pumps and anesthesia puncture kits, among other products which are sold under the Company’s own brands and are also sourced and distributed from other manufacturers. The Company has received an international “CE” certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for over 20 Class I products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for more than 30 years, providing over 1,000 types of products for domestic sales, as well as over 120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania.

For more information, please visit www.meihuamed.com.

Follow us on Webull: https://www.webull.com/quote/nasdaq-mhua

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, and its ability to fully execute on the planned agreement, the Company’s future business development and plans of future business development, including its ability to successfully develop robotic assisted surgery systems and obtain licensure and certification for such systems, financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in China, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, including under the section entitled “Risk Factors” in its annual report on Form 20-F, as well as on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:

IR Department
Email: secretary@meihuamed.com
Tel: +86-0514-89800199

Christensen
Yang Song
Email: yang.song@christensencomms.com
Tel: +86-010-59001548

Regent Hong Kong’s Terrace Suite Goes Viral After iShowSpeed Livestream – Luxury Experience Captures Asia’s Attention

HONG KONG SAR – Media OutReach Newswire – 25 April 2025 – The global spotlight has turned to Hong Kong’s luxury hospitality scene following an impromptu livestream by internationally known content creator iShowSpeed, who recently shared his experience staying in the Terrace Suite at Regent Hong Kong. His enthusiastic reaction, broadcast live to millions of followers, has since gone viral across digital platforms — generating global buzz and positioning the suite as one of the most talked-about luxury stays in Asia.

Described by iShowSpeed as the “best hotel in China”, the Terrace Suite delivers on that claim with a two-storey, 5,500-square-foot layout that blends opulent comfort with cinematic views of Victoria Harbour — a striking combination that’s now resonating with discerning travellers across Southeast Asia, including Singapore.

To see why this suite is generating so much attention, read more here: Terrace Suite at Regent Hong Kong Hotel – iShowSpeed’s Room Tour

A New Benchmark in Urban Luxury
The crown jewel of the newly reopened Regent Hong Kong, the Terrace Suite redefines luxury living in the heart of the city. Featuring a 3,300-square-foot private rooftop terrace with an outdoor whirlpool, plush seating, and dining space with skyline views, the suite offers guests an exclusive escape that feels both intimate and grand.

Inside, guests are welcomed by an expansive living and dining area, entertainment room, and the signature Oasis Bathroom complete with a round soaking tub and floor-to-ceiling windows. Smart technology, high-speed connectivity, and wellness-focused amenities complete the experience — tailored for today’s luxury travellers.

An Evolving Space for Celebration and Storytelling
While the Terrace Suite has long been a favourite for weddings and anniversaries, recent interest from content creators, digital influencers, and luxury seekers has expanded its appeal. Its stylish interiors, versatile dressing area, and stunning backdrop make it ideal for livestreams, product reveals, and milestone celebrations.

In Singapore — a key regional market for Hong Kong’s tourism revival — the viral attention surrounding the Terrace Suite has sparked strong interest among travellers seeking one-of-a-kind experiences. With direct flight access, a high affinity for luxury travel, and growing interest in cultural crossovers, Singaporean visitors are now eyeing Regent Hong Kong as a must-visit destination for 2025.

A Regal Return to the World Stage
Regent Hong Kong’s reemergence into the global travel scene comes at a time when Hong Kong is actively reinviting the world. The viral success of the Terrace Suite marks not just a moment of social media fame, but a signal of the city’s renewed luxury tourism offering — refined, bold, and globally relevant.

Hashtag: #RegentHongKong #TerraceSuite #IShowSpeed



The issuer is solely responsible for the content of this announcement.

About Regent Hong Kong

Situated along the Victoria Harbour waterfront, Regent Hong Kong combines legendary heritage with modern elegance. As part of IHG Hotels & Resorts’ prestigious Regent brand, the hotel offers a collection of meticulously curated suites and experiences designed for the world’s most discerning travellers.

Xinhua Silk Road: 16th Potato Industry Development Conference held in E. China’s Tengzhou to promote industrial upgrading

BEIJING, April 25, 2025 /PRNewswire/ — The 16th Tengzhou Potato Industry Development Conference was held recently in Tengzhou, east China’s Shandong Province, with an aim of promoting industrial upgrading and tapping development potential.

As the largest dual-season potato production area in China, Shandong has propelled the industry forward through technological innovation and market-oriented strategies, fostering development toward scale, standardization, and branding. Tengzhou, as the core production area, boasts 700,000 mu of spring and autumn potato cultivation with an annual output of 2.6 million tonnes.

In recent years, Tengzhou has adopted a “big agriculture” philosophy to build a full industrial chain integrating production, processing, sales, and agri-tourism. The city is committed to becoming a trendsetter in China’s table potato sector.

During the conference, guests conducted field visits to variety demonstration plots, harvesting bases, and trading centers, and participated in thematic discussions on industry technologies and market trends. The achievements of Tengzhou’s potato industry received high praise from attendees.

Looking ahead, Tengzhou plans to use the conference as a platform to strengthen communication and foster mutually beneficial cooperation, transforming the “small potato” into a “big industry” and contributing to increased industry efficiency, higher farmer incomes, and agricultural development.

Original link: https://en.imsilkroad.com/p/345366.html

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

CHENGDU, China, April 25, 2025 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) (“Keymed” or the “Company”) today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), and is currently undergoing Phase I/II clinical trials in China for the treatment of solid tumors. This milestone marks another breakthrough in Keymed’s ADC drug development, further strengthening its innovative therapeutic pipeline in oncology.

CM518D1: a novel ADC drug targeting CDH17

CDH17 (Cadherin-17), a member of the cadherin superfamily, is an emerging therapeutic target in gastrointestinal cancers. Studies indicate that CDH17 is highly expressed in multiple gastrointestinal cancers including colorectal cancer, gastric cancer, pancreatic cancer, esophageal cancer, and plays a critical role in tumor invasion and metastasis.

CM518D1 delivers cytotoxic payloads precisely to tumor cells by a CDH17-specific monoclonal antibody, which combines the specificity of antibodies and the potent cytotoxicity of chemotherapeutics. Preclinical studies demonstrated that CM518D1 exhibits strong direct cytotoxic activity, potent bystander killing effect and excellent plasma stability. CM518D1 exhibits remarkable anti-tumor efficacy in multiple solid tumor xenograft models and a favorable safety profile and wide therapeutic window in toxicological evaluations.

Clinical development: providing a potential treatment regimen for gastrointestinal cancers

Keymed is currently conducting Phase I/II clinical trials in China to evaluate the safety, tolerability, and preliminary efficacy of CM518D1 in patients with advanced solid tumors. Future studies aim to provide a more precise, effective, and safe therapeutic option for patients worldwide with gastrointestinal cancers.

Keymed’s ADC platform: a next-generation of proprietary ADC program for innovative drug development

Keymed’s proprietary ADC platform has capabilities for developing next-generation ADCs with novel payloads (e.g., diverse mechanisms of action), hydrophilic linkers (optimized for stability and drug release) and engineered antibodies (enhanced binding and pharmacokinetics).

To meet the demands of next-generation ADC development and clinical research, Keymed has established GMP-compliant facilities for linker-payload and ADC drug substance production. This infrastructure positions Keymed at the forefront of ADC therapeutic development, helping to address unmet medical needs for patients worldwide.

About Keymed Biosciences

Keymed Biosciences Inc. (HKEX: 02162) is a biotech company focused on the urgent unmet clinical needs, and committed to providing high-quality, affordable, innovative therapies for patients in China and overseas. Keymed was founded by medical and scientific experts who have strong experience in the transformation of scientific and technological achievements to commercialization at home and abroad.

Lao Police Arrest 26 in Illegal Surrogacy Operation in Luang Namtha

The suspects (Photo: Lao security News)

Lao authorities have arrested 26 individuals, including three Chinese nationals, for their involvement in an illegal surrogacy operation uncovered at a public hospital in Luang Namtha Province on 3 April.

Weibo Corporation to Report First Quarter 2025 Financial Results on May 21, 2025

BEIJING, April 25, 2025 /PRNewswire/ — Weibo Corporation (NASDAQ: WB and HKEX: 9898), a leading social media for people to create, share and discover content, will announce its unaudited financial results for the first quarter 2025 before the U.S. market opens on Wednesday, May 21, 2025. Following the announcement, Weibo’s management team will host a conference call from 7 AM8 AM Eastern Time on May 21, 2025 (or 7 PM8 PM Beijing Time on May 21, 2025) to present an overview of the Company’s financial performance and business operations.

Participants who wish to dial in to the teleconference must register through the below public participant link. Dial in and instruction will be in the confirmation email upon registering.

Participants Registration Link:
https://register-conf.media-server.com/register/BIbb5c504e4aeb43a380f69d373cfb8ca0

Additionally, a live and archived webcast of this conference call will be available at http://ir.weibo.com.

About Weibo Corporation

Weibo is a leading social media for people to create, share and discover content online. Weibo combines the means of public self-expression in real time with a powerful platform for social interaction, content aggregation and content distribution. Any user can create and post a feed and attach multi-media and long-form content. User relationships on Weibo may be asymmetric; any user can follow any other user and add comments to a feed while reposting. This simple, asymmetric and distributed nature of Weibo allows an original feed to become a live viral conversation stream.

Weibo enables its advertising and marketing customers to promote their brands, products and services to users. Weibo offers a wide range of advertising and marketing solutions to companies of all sizes. The Company generates a substantial majority of its revenues from the sale of advertising and marketing services, including the sale of social display advertisement and promoted marketing offerings. Designed with a “mobile first” philosophy, Weibo displays content in a simple information feed format and offers native advertisement that conform to the information feed on our platform. To support the mobile format, we have developed and continuously refining our social interest graph recommendation engine, which enables our customers to perform people marketing and target audiences based on user demographics, social relationships, interests and behaviors, to achieve greater relevance, engagement and marketing effectiveness

Contact:

Investor Relations
Weibo Corporation
Phone: +86 10 5898-3336
Email: ir@staff.weibo.com